Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation

View ORCID ProfileRónán Daly, Gavin Blackburn, View ORCID ProfileManikhandan Mudaliar, View ORCID ProfileKarl Burgess, Anne Stirling, View ORCID ProfileDuncan Porter, View ORCID ProfileIain McInnes, View ORCID ProfileMichael P. Barrett, View ORCID ProfileJames Dale
doi: https://doi.org/10.1101/19001594
Rónán Daly
1University of Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rónán Daly
Gavin Blackburn
1University of Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manikhandan Mudaliar
1University of Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Manikhandan Mudaliar
Karl Burgess
2University of Edinburgh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karl Burgess
Anne Stirling
3Gartnavel General Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan Porter
1University of Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Duncan Porter
Iain McInnes
1University of Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Iain McInnes
Michael P. Barrett
1University of Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael P. Barrett
James Dale
1University of Glasgow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Dale
  • For correspondence: jamesdale1@nhs.net
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To characterize changes in the plasma metabolic profile in newly diagnosed rheumatoid arthritis (RA) patients upon commencement of conventional disease modifying anti-rheumatic drug (cDMARD) therapy.

Methods Plasma samples collected in an early RA randomized strategy study (NCT00920478) that compared clinical (DAS) disease activity assessment with musculoskeletal ultrasound assessment (MSUS) to drive treatment decisions were subjected to untargeted metabolomic analysis. Metabolic profiles were collected at pre- and 3 months post commencement of non-biologic cDMARD. Metabolites that changed in association with changes in the DAS44 score were identified at the 3 month timepoint.

Results A total of ten metabolites exhibited a clear correlation with reduction in DAS44 score following cDMARD commencement, particularly itaconate, its derived anhydride and a derivative of itaconate coA. Increasing itaconate correlated with improved DAS44 score and decreasing levels of CRP.

Conclusion cDMARD treatment effects invoke consistent changes in plasma detectable metabolites, that in turn implicate clinical disease activity with macrophages. Such changes inform RA pathogenesis and reveal for the first time a link between itaconate production and resolution of an inflammatory disease in humans. Quantitative metabolic biomarker based tests of clinical change in state are feasible and should be developed around the itaconate pathway.

What is already known about this subject?Rheumatoid arthritis is associated with perturbations in metabolic activity, which have also been associated with response to certain treatments. In vitro work on immunometabolism has recently revealed itaconate as a key metabolite controlling macrophage activation.

What does this study add?In newly diagnosed RA, commencement of csDMARD therapy is associated with changes in the levels of ten metabolites (especially itaconate and its derivatives) that correlate to a corresponding fall in disease activity Pathway analyses suggest these metabolites are associated with macrophage activation.

How might this impact on clinical practice?Changes in metabolite levels in response to treatment provide additional new insights into RA pathogenesis that suggest a focus on macrophage activation state. The association of increased itaconate with decreased inflammation point to possible routes of intervention in RA.

Competing Interest Statement

RD, GB, KB, DP and MB have nothing to disclose. MM reports other support from CEREVANCE, LTD, outside the submitted work. AS reports grants from Pfizer UK, during the conduct of this survey. IM reports grants from Pfizer, grants from Chief Scientist Office, grants from ARUK, during the conduct of the study; grants and personal fees from BMS, personal fees from Abbvie, grants and personal fees from UCB, grants and personal fees from Pfizer, grants and personal fees from Janssen, personal fees from Lilly, outside the submitted work. JD reports grants from Chief Scientist’s Office, Scottish Government and from Pfizer UK during the conduct of the study; non-financial support from Abbvie UK, outside the submitted work.

Clinical Trial

NCT00920478

Funding Statement

The TaSER study was jointly funded by a Clinical Academic Fellowship from the Chief Scientist?s Office, Scottish Executive and an Investigator Initiated project grant from Pfizer UK. The metabolomics study was funded by an additional Investigator Initiated project grant from Pfizer UK. RD was funded by Wellcome (105614/Z/14/Z). MPB is part of the Wellcome Centre for Molecular Parasitology funded by a core grant from Wellcome (104111/Z/14/Z).

Author Declarations

All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.

Yes

Footnotes

  • Funders: The TaSER study was jointly funded by a Clinical Academic Fellowship from the Chief Scientist’s Office, Scottish Executive and an Investigator Initiated project grant from Pfizer UK. The metabolomics study was funded by an additional Investigator Initiated project grant from Pfizer UK. RD was funded by Wellcome (105614/Z/14/Z). MPB is part of the Wellcome Centre for Molecular Parasitology funded by a core grant from Wellcome (104111/Z/14/Z).

  • Competing Interests: RD, GB, KB, DP and MB have nothing to disclose. MM reports other support from CEREVANCE, LTD, outside the submitted work. AS reports grants from Pfizer UK, during the conduct of this survey. IM reports grants from Pfizer, grants from Chief Scientist Office, grants from ARUK, during the conduct of the study; grants and personal fees from BMS, personal fees from Abbvie, grants and personal fees from UCB, grants and personal fees from Pfizer, grants and personal fees from Janssen, personal fees from Lilly, outside the submitted work. JD reports grants from Chief Scientist’s Office, Scottish Government and from Pfizer UK during the conduct of the study; non-financial support from Abbvie UK, outside the submitted work.

Data Availability

Please contact the corresponding author in regards to accessing the experimental data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 08, 2019.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation
Rónán Daly, Gavin Blackburn, Manikhandan Mudaliar, Karl Burgess, Anne Stirling, Duncan Porter, Iain McInnes, Michael P. Barrett, James Dale
medRxiv 19001594; doi: https://doi.org/10.1101/19001594
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation
Rónán Daly, Gavin Blackburn, Manikhandan Mudaliar, Karl Burgess, Anne Stirling, Duncan Porter, Iain McInnes, Michael P. Barrett, James Dale
medRxiv 19001594; doi: https://doi.org/10.1101/19001594

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Rheumatology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (173)
  • Epidemiology (4906)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (86)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5408)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1832)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (38)